Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor

por Serrano, César, Fletcher, Jonathan A.
Publicado 2019

The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma

por Wu, Xinqi, Zhu, Meijun, Fletcher, Jonathan A., Giobbie-Hurder, Anita, Hodi, F. Stephen
Publicado 2012

Comparative Gene Expression Profiling of Benign and Malignant Lesions Reveals Candidate Therapeutic Compounds for Leiomyosarcoma

por Edris, Badreddin, Fletcher, Jonathan A., West, Robert B., van de Rijn, Matt, Beck, Andrew H.
Publicado 2012

Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor

por Mühlenberg, Thomas, Grunewald, Susanne, Treckmann, Jürgen, Podleska, Lars, Schuler, Martin, Fletcher, Jonathan A., Bauer, Sebastian
Publicado 2015

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

por Nakayama, Robert, Zhang, Yi-Xiang, Czaplinski, Jeffrey T., Anatone, Alex J., Sicinska, Ewa T., Fletcher, Jonathan A., Demetri, George D., Wagner, Andrew J.
Publicado 2016

YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways

por Ou, Wen-Bin, Lundberg, Meijun Z., Zhu, Shuihao, Bahri, Nacef, Kyriazoglou, Anastasios, Xu, Liangliang, Chen, Ting, Mariño-Enriquez, Adrian, Fletcher, Jonathan A.
Publicado 2021

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3

por Yang, Peipei, Chen, Weicai, Li, Xuhui, Eilers, Grant, He, Quan, Liu, Lili, Wu, Yeqing, Wu, Yuehong, Yu, Wei, Fletcher, Jonathan A., Ou, Wen-Bin
Publicado 2016

AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression

por Song, Wei, Wang, Hao, Lu, Minmin, Ni, Xinxin, Bahri, Nacef, Zhu, Shuihao, Chen, Limin, Wu, Yuehong, Qiu, Jieqiong, Fletcher, Jonathan A., Ou, Wen-Bin
Publicado 2020

Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53

por Ou, Wen-Bin, Lu, Minmin, Eilers, Grant, Li, Hailong, Ding, Jiongyan, Meng, Xuli, Wu, Yuehong, He, Quan, Sheng, Qing, Zhou, Hai-Meng, Fletcher, Jonathan A
Publicado 2016

p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors

por Henze, Joern, Mühlenberg, Thomas, Simon, Susanne, Grabellus, Florian, Rubin, Brian, Taeger, Georg, Schuler, Martin, Treckmann, Juergen, Debiec-Rychter, Maria, Taguchi, Takahiro, Fletcher, Jonathan A., Bauer, Sebastian
Publicado 2012

Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor

por Katz, Steven C, Burga, Rachel A, Naheed, Seema, Licata, Lauren A, Thorn, Mitchell, Osgood, Doreen, Nguyen, Cang T, Espat, N Joseph, Fletcher, Jonathan A, Junghans, Richard P
Publicado 2013

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma

por Klug, Lillian R., Bannon, Amber E., Javidi-Sharifi, Nathalie, Town, Ajia, Fleming, William H., VanSlyke, Judy, Musil, Linda, Fletcher, Jonathan A., Tyner, Jeffrey W., Heinrich, Michael C.
Publicado 2018

HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status

por Ou, Wen-Bin, Zhu, Jiaqing, Eilers, Grant, Li, Xuhui, Kuang, Ye, Liu, Li, Mariño-Enríquez, Adrián, Yan, Ziqin, Li, Hailong, Meng, Fanguo, Zhou, Haimeng, Sheng, Qing, Fletcher, Jonathan A.
Publicado 2015

Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours

por Huang, Mengyuan, Yang, Wenyu, Zhu, Jiaqing, Mariño-Enríquez, Adrián, Zhu, Chennianci, Chen, Jiaming, Wu, Yuehong, Quan, Yanping, Qiu, Haibo, Li, Xuhui, Chai, Li, Fletcher, Jonathan A., Ou, Wen-Bin
Publicado 2019

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

por George, Suzanne, von Mehren, Margaret, Fletcher, Jonathan A., Sun, Jichao, Zhang, Sen, Pritchard, Justin R., Hodgson, John Graeme, Kerstein, David, Rivera, Victor M., Haluska, Frank G., Heinrich, Michael C.
Publicado 2022

Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma

por Fiorito, Elisa, Szybowska, Patrycja, Haugsten, Ellen M., Kostas, Michal, Øy, Geir F., Wiedlocha, Antoni, Singh, Sachin, Nakken, Sigve, Mælandsmo, Gunhild M., Fletcher, Jonathan A., Meza-Zepeda, Leonardo A., Wesche, Jørgen
Publicado 2022

ETV1 is a lineage-specific survival factor in GIST and cooperates with KIT in oncogenesis

por Chi, Ping, Chen, Yu, Zhang, Lei, Guo, Xingyi, Wongvipat, John, Shamu, Tambudzai, Fletcher, Jonathan A., Dewell, Scott, Maki, Robert G., Zheng, Deyou, Antonescu, Cristina R., Allis, C. David, Sawyers, Charles L.
Publicado 2010

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone

por Peterse, Elisabeth F. P., Cleven, Arjen H. G., De Jong, Yvonne, Briaire-de Bruijn, Inge, Fletcher, Jonathan A., Danen, Erik H. J., Cleton-Jansen, Anne-Marie, Bovée, Judith V. M. G.
Publicado 2016

BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor

por Tsai, Hui‐Jen, Jiaang, Weir‐Torn, Shih, Neng‐Yao, Fletcher, Jonathan A., Lin, Ming‐Jon, Yang, Ming‐Yu, Chen, Chiung‐Tong, Hsu, Tsu‐An John, Wu, Chun‐Chieh, Lin, Hui‐You, Chen, Li‐Tzong
Publicado 2018

Targeting SALL4 by entinostat in lung cancer

por Yong, Kol Jia, Li, Ailing, Ou, Wen-Bin, Hong, Clarice Kit Yee, Zhao, Wenxiu, Wang, Fei, Tatetsu, Hiro, Yan, Benedict, Qi, Lihua, Fletcher, Jonathan A., Yang, Henry, Soo, Ross, Tenen, Daniel G., Chai, Li
Publicado 2016